Comparative Pharmacology
Head-to-head clinical analysis: CHLORHEXIDINE GLUCONATE versus PHISOHEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORHEXIDINE GLUCONATE versus PHISOHEX.
CHLORHEXIDINE GLUCONATE vs PHISOHEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cationic bisbiguanide that disrupts microbial cell membranes by binding to negatively charged cell wall components, increasing permeability and causing leakage of cytoplasmic contents; also inhibits bacterial enzymes and precipitates cytoplasmic constituents.
Disrupts bacterial cell wall synthesis by binding to the bacterial ribosome and inhibiting protein synthesis; also has surfactant properties that disrupt bacterial cell membrane integrity.
Oral rinse: 15 mL of 0.12% solution swished in mouth for 30 seconds twice daily; topical: apply 2% cream or lotion to affected area 2-3 times daily.
Apply topically as a 3% emulsion to affected area, rinse thoroughly; typically used 1-2 times daily for up to 10 days.
None Documented
None Documented
Terminal half-life approximately 12-24 hours; may be prolonged in hepatic impairment.
Terminal elimination half-life approximately 6-7 hours in adults with normal renal function. Prolonged in renal impairment (up to 20 hours) due to reduced clearance of active metabolite (pentachlorophenol).
Primarily renal (10-30% unchanged) and biliary/fecal (majority as metabolites).
Renal (biliary/fecal negligible). Up to 10% of dose excreted unchanged in urine; remainder as metabolites (glucuronide and sulfate conjugates).
Category C
Category C
Antiseptic
Antiseptic